Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: To compare clinico-pathologic variables and protein expression of potential regulatory components in patients who develop type II endometrial cancer with and without antecedent tamoxifen.
Methods: Clinico-pathologic variables were compared for all surgically staged patients (2000-2008) with grade 3 endometrioid, papillary serous, clear cell, and carcinosarcoma of the uterus based on tamoxifen exposure [Tam (+) vs. Tam (-)]. Overall survival was analyzed using a multivariable Cox regression model and Kaplan-Meier estimates. Protein expression of ERα, PR, mTOR, p-mTOR, IGF-1R, EGFR, VEGF and HER-2/neu was compared by immunohistochemistry using a semiquantitative scoring system.
Results: Of 115 patients with high grade endometrial cancers, 15 received tamoxifen. These patients were older at diagnosis than Tam (-) patients. A higher percentage of Tam (+) patients had carcinosarcoma compared to Tam (-) patients (60% vs. 30%, P=0.038). Overall survival for Tam (+) patients was shorter than Tam (-) patients (16.6 vs. 32.2 months, P=0.004). The hazard ratio for death for Tam (+) patients was 2.53 (P=0.014), controlling for age and stage. Intensity and extent of staining were similar for ERα, PR, VEGF, EGFR, p-mTOR and HER-2/neu. The average expression score for IGF-1R and mTOR in the Tam (+) group was significantly higher than the Tam (-) group: 10.3 vs 7.0, P=0.001 and 6.0 vs 3.1, P=0.029, respectively.
Conclusion: There are differences in the biology of type II endometrial cancers that develop in women with prior tamoxifen exposure. Tamoxifen associated cancers show higher expression of IGF-1R and mTOR, which should be further investigated.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ygyno.2012.07.105 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Outcomes following transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from ASPEN.
Blood Adv
September 2025
Alfred Health and Monash University, East Melbourne, Australia.
Zanubrutinib is a next-generation covalent Bruton tyrosine kinase (BTK) inhibitor designed to provide complete and sustained BTK occupancy for efficacy across disease-relevant tissues, with fewer off-target adverse events (AEs) than other covalent BTK inhibitors. In the phase 3 ASPEN study (BGB-3111-302), comparable efficacy and a favorable safety profile versus ibrutinib were demonstrated in patients with MYD88-mutated Waldenström macroglobulinemia (WM), leading to approval of zanubrutinib for patients with WM. BGB-3111-LTE1 (LTE1) is a long-term extension study to which eligible patients, including patients from comparator treatment arms, could enroll following participation in various parent studies of zanubrutinib to treat B-cell malignancies.
View Article and Find Full Text PDFRutin Alleviates Breast Cancer Resistance to Tamoxifen By Downregulating ABC Transporters, Inducing ROS Generation and Resetting Redox Status.
J Biochem Mol Toxicol
September 2025
Biochemistry Division, Chemistry Department, Faculty of Science, Tanta University, Tanta, Egypt.
Breast cancer is one of the most lethal cancers in women worldwide. Tamoxifen (TAM), a nonsteroidal antiestrogen, is a highly successful treatment for breast cancer. However, developed resistance to TAM can substantially impair chemotherapy efficacy, resulting in poor prognosis and cancer recurrence.
View Article and Find Full Text PDFSwitching Patients with Schizophrenia from Intramuscular Paliperidone Palmitate Once Monthly to TV-46000, a Long-Acting Subcutaneous Antipsychotic: Population Pharmacokinetic-Based Strategies.
Adv Ther
September 2025
Teva Branded Pharmaceutical Products R&D LLC, West Chester, PA, USA.
Introduction: Pharmacokinetic differences between long-acting injectable antipsychotic (LAI) formulations, combined with a lack of clinical switch studies, contribute to clinician uncertainty when transitioning between LAIs. This analysis employed a population pharmacokinetic (popPK) modeling approach to characterize dosing conversions and switching strategies from intramuscular paliperidone palmitate once monthly (PP1m) to TV-46000, a long-acting subcutaneous formulation of risperidone, once monthly (q1m), with a secondary analysis of PP1m to TV-46000 every 2 months (q2m).
Methods: For PP1m and TV-46000, concentration-time profiles for paliperidone and TV-46000 total active moiety (TAM; risperidone + paliperidone) were simulated on the basis of published popPK models with virtual populations of 5000 patients.
Ultrasound-Based Assessment of Rectus Femoris Muscle Wasting as a Predictor of 28-Day Mortality in Septic Shock: A Prospective Study.
J Intensive Care Med
September 2025
Medical Intensive Care Unit, 108 Military Central Hospital, Hanoi, Vietnam.
Background: Bedside ultrasound is increasingly utilized to assess muscle mass in critically ill patients, providing a noninvasive and real-time tool for early risk stratification. Muscle wasting is known to be associated with adverse outcomes in septic shock, but its prognostic value using ultrasound in this population remains underexplored. This study aimed to investigate the association between changes in rectus femoris cross-sectional area (CSA), assessed by bedside ultrasound, and 28-day mortality in patients with septic shock.
View Article and Find Full Text PDFInvestigating the Effects of Meditation, Nature Sounds, and Music on the Patient Experience During Intravitreal Injections.
Cureus
August 2025
Retina Division, University of California, Los Angeles (UCLA) Jules Stein Eye Institute, Los Angeles, USA.
Introduction: The purpose of this study was to evaluate the effects of three brief interventions (spoken/guided meditation, nature sounds, or music) on patients' subjective experience with intravitreal injections (IVIs).
Methods: A total of 121 consecutive patients were randomized into four cohorts: spoken/guided meditation (n = 31), nature sounds (n = 30), music (classical or jazz, n = 30), and control (n = 30). Subjective anxiety levels were recorded prior to and following a three- to five-minute intervention in the first three study groups as well as following the IVI.